Literature DB >> 23304031

Current and future options for treating esophageal cancer: a paradigm shift toward organ-sparing therapies.

Wayne Hofstetter1.   

Abstract

Entities:  

Keywords:  Antineoplastic combined chemotherapy protocols; carcinoma, squamous cell; chemoradiotherapy; combined modality therapy; esophageal neoplasms/drug therapy/radiotherapy/surgery; esophagectomy; lymphatic metastasis; neoadjuvant therapy; neoplasm recurrence, local; neoplasm staging; salvage therapy

Mesh：

Year:  2012        PMID： 23304031      PMCID： PMC3528248     

Source DB:  PubMed          Journal:  Tex Heart Inst J        ISSN： 0730-2347


× No keyword cloud information.
  7 in total

1.  Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus.

Authors:  Michael Stahl; Martin Stuschke; Nils Lehmann; Hans-Joachim Meyer; Martin K Walz; Siegfried Seeber; Bodo Klump; Wilfried Budach; Reinhard Teichmann; Marcus Schmitt; Gerd Schmitt; Claus Franke; Hansjochen Wilke
Journal:  J Clin Oncol       Date:  2005-04-01       Impact factor: 44.544

2.  Does the timing of esophagectomy after chemoradiation affect outcome?

Authors:  Jae Y Kim; Arlene M Correa; Ara A Vaporciyan; Jack A Roth; Reza J Mehran; Garrett L Walsh; David C Rice; Jaffer A Ajani; Dipen M Maru; Manoop S Bhutani; James Welsh; Edith M Marom; Stephen G Swisher; Wayne L Hofstetter
Journal:  Ann Thorac Surg       Date:  2011-10-01       Impact factor: 4.330

3.  Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102.

Authors:  Laurent Bedenne; Pierre Michel; Olivier Bouché; Chantal Milan; Christophe Mariette; Thierry Conroy; Denis Pezet; Bernard Roullet; Jean-François Seitz; Jean-Philippe Herr; Bernard Paillot; Patrick Arveux; Franck Bonnetain; Christine Binquet
Journal:  J Clin Oncol       Date:  2007-04-01       Impact factor: 44.544

4.  The prevalence of lymph node metastases in patients with T1 esophageal adenocarcinoma a retrospective review of esophagectomy specimens.

Authors:  Jessica M Leers; Steven R DeMeester; Arzu Oezcelik; Nancy Klipfel; Shahin Ayazi; Emmanuele Abate; Jörg Zehetner; John C Lipham; Linda Chan; Jeffrey A Hagen; Tom R DeMeester
Journal:  Ann Surg       Date:  2011-02       Impact factor: 12.969

5.  Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group.

Authors:  J S Cooper; M D Guo; A Herskovic; J S Macdonald; J A Martenson; M Al-Sarraf; R Byhardt; A H Russell; J J Beitler; S Spencer; S O Asbell; M V Graham; L L Leichman
Journal:  JAMA       Date:  1999-05-05       Impact factor: 56.272

6.  A Phase II study of a paclitaxel-based chemoradiation regimen with selective surgical salvage for resectable locoregionally advanced esophageal cancer: initial reporting of RTOG 0246.

Authors:  Stephen G Swisher; Kathryn A Winter; Ritsuko U Komaki; Jaffer A Ajani; Tsung T Wu; Wayne L Hofstetter; Andre A Konski; Christopher G Willett
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-04-18       Impact factor: 7.038

7.  Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagus.

Authors:  O Pech; A Behrens; A May; L Nachbar; L Gossner; T Rabenstein; H Manner; E Guenter; J Huijsmans; M Vieth; M Stolte; C Ell
Journal:  Gut       Date:  2008-05-06       Impact factor: 23.059
  7 in total
  1 in total

Review 1.  Surveillance versus esophagectomy in esophageal cancer patients with a clinical complete response after induction chemoradiation.

Authors:  Tara R Semenkovich; Bryan F Meyers
Journal:  Ann Transl Med       Date:  2018-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.